Related Experiment Video
Updated: May 1, 2026

Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK
Published on: December 18, 2012
Valacyclovir therapy does not reverse herpes-associated alterations in cervical immunology: a randomized,
Tae Joon Yi1, Brett Shannon1, Lisungu Chieza2
1Department of Medicine Department of Immunology.
Abstract:
Herpes simplex virus type 2 (HSV-2) infection is associated with a 3-fold increase in the risk of human immunodeficiency virus (HIV) acquisition, perhaps through alterations in mucosal HIV-susceptible target cells. We performed a clinical trial to assess the impact of herpes therapy on cervical immunology in HSV-2-infected, HIV-uninfected women from Africa or the Caribbean who were living in Toronto, Canada. Thirty participants received 1 g of valacyclovir orally each day for 2 months in a randomized double-blind, placebo-controlled, crossover trial. Valacyclovir did not reduce the number of cervical CD4(+) T cells, the number of dendritic cells, or the expression of proinflammatory cytokines and tended to increase the expression of the HIV coreceptor CCR5 and the activation marker CD69. Short-term valacyclovir therapy did not reverse HSV-2-associated alterations in genital immunology. Clinical Trials Registration. NCT00946556.
Related Concept Videos
Cytomegalovirus Disease
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Crossover Experiments
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Retroviruses
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

